Bangor Savings Bank boosted its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 1.2% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 13,960 shares of the biopharmaceutical company’s stock after buying an additional 161 shares during the period. Bangor Savings Bank’s holdings in Gilead Sciences were worth $948,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently added to or reduced their stakes in GILD. Hall Laurie J Trustee increased its stake in Gilead Sciences by 20.0% in the first quarter. Hall Laurie J Trustee now owns 1,500 shares of the biopharmaceutical company’s stock worth $100,000 after buying an additional 250 shares during the last quarter. Cable Hill Partners LLC increased its stake in Gilead Sciences by 51.9% in the first quarter. Cable Hill Partners LLC now owns 1,584 shares of the biopharmaceutical company’s stock worth $107,000 after buying an additional 541 shares during the last quarter. Dubuque Bank & Trust Co. increased its stake in Gilead Sciences by 19.4% in the first quarter. Dubuque Bank & Trust Co. now owns 1,642 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 267 shares during the last quarter. Webster Bank N. A. increased its stake in Gilead Sciences by 51.7% in the first quarter. Webster Bank N. A. now owns 1,831 shares of the biopharmaceutical company’s stock worth $125,000 after buying an additional 624 shares during the last quarter. Finally, Thomas J. Herzfeld Advisors Inc. purchased a new stake in Gilead Sciences during the fourth quarter worth $143,000. Institutional investors own 74.03% of the company’s stock.

Gilead Sciences, Inc. (GILD) opened at 73.76 on Friday. Gilead Sciences, Inc. has a one year low of $63.76 and a one year high of $88.85. The stock’s 50 day moving average price is $68.32 and its 200-day moving average price is $68.63. The company has a market capitalization of $96.38 billion, a P/E ratio of 7.80 and a beta of 1.21.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Tuesday, May 2nd. The biopharmaceutical company reported $2.20 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.18 by $0.02. The firm had revenue of $6.51 billion during the quarter, compared to analysts’ expectations of $6.66 billion. Gilead Sciences had a return on equity of 76.64% and a net margin of 43.42%. Equities analysts forecast that Gilead Sciences, Inc. will post $8.41 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, June 29th. Stockholders of record on Friday, June 16th were given a $0.52 dividend. The ex-dividend date was Wednesday, June 14th. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.82%. Gilead Sciences’s payout ratio is 21.99%.

WARNING: “Bangor Savings Bank Purchases 161 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)” was posted by Daily Political and is the sole property of of Daily Political. If you are accessing this news story on another site, it was illegally stolen and reposted in violation of United States and international trademark and copyright law. The legal version of this news story can be viewed at https://www.dailypolitical.com/2017/07/22/bangor-savings-bank-purchases-161-shares-of-gilead-sciences-inc-nasdaqgild.html.

A number of analysts recently weighed in on the company. Jefferies Group LLC restated a “hold” rating and issued a $80.00 target price on shares of Gilead Sciences in a research report on Tuesday, July 11th. Zacks Investment Research downgraded Gilead Sciences from a “buy” rating to a “hold” rating in a research report on Tuesday. Robert W. Baird restated an “outperform” rating and issued a $87.00 target price on shares of Gilead Sciences in a research report on Thursday, July 13th. Morgan Stanley restated an “equal weight” rating on shares of Gilead Sciences in a research report on Tuesday, July 11th. Finally, Cowen and Company reaffirmed an “outperform” rating and issued a $90.00 price target on shares of Gilead Sciences in a research note on Wednesday, July 5th. One investment analyst has rated the stock with a sell rating, fourteen have assigned a hold rating, fourteen have given a buy rating and two have given a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $80.24.

In other news, insider John C. Martin sold 73,333 shares of the firm’s stock in a transaction on Monday, July 3rd. The stock was sold at an average price of $71.00, for a total value of $5,206,643.00. Following the completion of the sale, the insider now owns 3,199,969 shares of the company’s stock, valued at approximately $227,197,799. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director John Francis Cogan sold 9,943 shares of the firm’s stock in a transaction on Tuesday, May 9th. The stock was sold at an average price of $67.25, for a total value of $668,666.75. Following the completion of the sale, the director now directly owns 47,562 shares of the company’s stock, valued at approximately $3,198,544.50. The disclosure for this sale can be found here. Insiders sold a total of 88,276 shares of company stock valued at $6,230,610 in the last three months. Insiders own 1.30% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.